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Abstract
Women are more susceptible to a variety of autoimmune diseases including systemic lupus erythematosus (SLE),
multiple sclerosis (MS), primary biliary cirrhosis, rheumatoid arthritis and Hashimoto’s thyroiditis. This increased
susceptibility in females compared to males is also present in animal models of autoimmune diseases such as
spontaneous SLE in (NZBxNZW)F1 and NZM.2328 mice, experimental autoimmune encephalomyelitis (EAE) in SJL
mice, thyroiditis, Sjogren’s syndrome in MRL/Mp-lpr/lpr mice and diabetes in non-obese diabetic mice. Indeed,
being female confers a greater risk of developing these diseases than any single genetic or environmental risk
factor discovered to date. Understanding how the state of being female so profoundly affects autoimmune disease
susceptibility would accomplish two major goals. First, it would lead to an insight into the major pathways of
disease pathogenesis and, secondly, it would likely lead to novel treatments which would disrupt such pathways.
Why study sex differences?
Translational research which starts with a clinical obser-
vation, such as the increased susceptibility to autoim-
mune disease in females, can be termed as a ‘bedside to
bench to bedside approach’.I nc o n t r a s tt ot h ec l a s s i c
‘bench to bedside’ approach, research that begins with a
clinical observation carries less inherent risk of failure.
In the ‘bench to bedside’ approach, a molecule of inter-
est is focused upon as a target to either block or
enhance because it is thought to be either disease pro-
moting or inhibiting, respectively. This is an immune
molecule in the case of autoimmune diseases. The
inherent risk of this approach is that, while a molecule
of interest may be key to a pathway in an in vitro cul-
ture, it may not be key in vivo in the animal model due
to redundant molecular pathways that exist in vivo.
Further, even when a molecule of interest appears to be
important in disease pathogenesis in a given animal
model, it may not be critical in human disease due to
differences in disease pathways in the outbred human
population. Thus, the vast majority of research avenues
focusing on a given molecule of interest do not ulti-
mately prove to be physiologically significant in human
disease. This results in very high costs for research and
development as only a few make it to the market as new
treatments. In contrast, the ‘beside to bench to bedside’
approach begins with a clinical observation that is
known to be physiologically relevant in the human dis-
ease. For example, in autoimmune disease, a major dis-
ease susceptibility factor is the state of being female. If
this were understood, one would have discovered some-
thing that is indeed physiologically significant. In order
to understand why being female confers increased sus-
ceptibility, one must next go to the bench, using in vitro
and in vivo systems to simulate this clinical observation
and dissect out its underlying aetiology. After one or
more molecules have been discovered which are respon-
sible for conferring increased susceptibility of females,
one can then go back to the bedside in the form of a
clinical trial to test whether targeting these molecules
results in disease modification. Since the ‘bedside to
bench to bedside’ research avenue initially began with a
known clinical observation, the risk that treatments tar-
geting pathways underlying this observation will be
clinically insignificant is reduced.
Notably, the study of sex differences is important for
both women and men with autoimmune diseases. The
goal of this research is not merely to discern what is
makes women more at risk but also what makes most
men less at risk. If a factor were identified in men that
confers disease protection in most, this may lead to
insight into why some males do, indeed, develop auto-
immune disease.
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translational research
Powerful tools have been developed to unravel mechan-
isms underlying sex differences in diseases. Sex hor-
mones and/or sex-linked gene inheritance may be
responsible for the enhanced susceptibility of females to
autoimmune diseases. As will be discussed in detail
below, genetically modified mice and molecular reagents
can be used to separate out sex hormone effects from
sex chromosome effects, as well as to identify which
hormone receptor or sex chromosome gene is involved
in a given process. Meanwhile, powerful observational
analyses of sex differences in a range of diseases are
beginning applied to data collected anecdotally as well
as in clinical trials.
Why, in light of the wealth of data on clinical obser-
vations and the sophistication of tools needed to ascer-
tain mechanisms of sex differences, are there so few
current clinical trials based on sex differences
research? A major obstacle is that large clinical trials
are very costly and companies must be able to recover
these costs by marketing products for the years during
which patent protection exists. Indeed, patent products
are in place for novel molecules of interest in the clas-
sic ‘bench to bedside’ approach extremely early during
development. Unfortunately, treatments evolving from
insights made through the study of sex differences may
ultimately entail the use of a product which cannot be
patented. For example, if a naturally occurring hor-
mone is the ultimate treatment identified, it cannot be
patent protected. Thus, even if trials with a hormone
were successful clinically, costs for large clinical trials
would be difficult to recover. Therefore, for financial
reasons, once it becomes clear that a product patent is
not attainable, development of a given product by a
company can be either halted or, perhaps, not even
pursued.
Development of products that cannot be patent pro-
tected would ultimately produce relatively inexpensive
treatments. This would be good for healthcare costs at
for both the individual and the population as a whole.
While some sex differences basic research and clinical
trials are funded by nonprofits agencies and philan-
thropy, the level is far less than that undertaken by the
pharmaceutical industry.
Finally, finding a new use for an old drug, develop-
ment of generics or other non-patentable products for a
new indication has a safety advantage. These drugs have
been used in hundreds of thousands of patients for dec-
ades and their safety profile is well characterized, often
with vast post marketing experience. Novel molecules
that are discovered, patented and developed by a phar-
maceutical company are in their relative infancy with
respect to their safety profile. Generally, they are initially
given to a few subjects for a few weeks and then
ultimately given to, at most, a few thousand subjects for
1-2 years in order to attain the Food and Drug Adminis-
tration approval. Unfortunately, during the post market-
ing experience, after thousands of patients have been
treated for longer periods of time, serous adverse effects
and even some deaths can occur.
Overall, sex differences research can lead to new
insights and treatments that will be more likely to have
clinically significant effects, will be safer and less
expensive.
The approach for studying sex differences using
multiple sclerosis (MS) as an example
This review will focus on the disease MS as an example
of how one may use the ‘bedside to bench to bedside’
approach. It outlines how one may take advantage of
the currently available information on clinical observa-
tions of sex differences in the disease, utilize powerful
tools to dissect out basic mechanisms and then translate
these findings to clinical trials. Thus, a brief description
of MS and its disease model will be presented below.
MS is a putative autoimmune demyelinating disease.
The target organ of the immune response is the central
nervous system (CNS). Clinically, patients present with
discrete episodes of neurological dysfunction which
initially improve over weeks to months. This is a
relapse. Hence, the early phase of the disease is the
relapsing remitting phase (RR) of MS. The RR MS is
characterized by large numbers of enhancing lesions on
brain magnetic resonance imaging (MRI) which are
thought to be biomarkers for inflammatory foci patholo-
gically and relapses clinically. Enhancing lesions resolve
after about 1-2 months and leave behind a hyperinten-
sity on T2 weighted imaging that may reflect scars or a
past lesion load. Clinically, over the course of weeks to
months, complete or partial recovery of function occurs
after a relapse. This RR phase of the disease is thought
to be principally driven by the inflammatory lesions and,
indeed, this early phase of MS has been shown to be
responsive to anti-inflammatory treatments such as
interferons [1-5]. Unfortunately, after years of carrying
the diagnosis of RR MS (5-15 years), most patients ‘tran-
sition’ to a more permanently debilitating form of the
disease. This later stage is called the secondary progres-
sive phase (SP) of MS. Patients with SP MS have fewer
enhancing lesions and fewer relapses, but the relapses
they have are associated with poorer recovery. On mag-
netic resonance imaging MRI atrophy accumulation
becomes apparent. There is also a progression of disabil-
ity, even in the absence of clear relapses, and less
responsiveness to anti-inflammatory medications [6,7].
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mation on MRI and a better correlation between disabil-
ity and atrophy. Anti-inflammatory therapies, which
reduce enhancing lesions on MRI and clinical relapses,
may delay atrophy and permanent disability accumula-
tion if taken early in disease but they do not prevent the
development of either. In summary, the RR MS phase is
considered to be a more inflammatory phase of the dis-
ease, while the SP MS phase is a more neurodegenera-
tive phase.
As is the case with most autoimmune diseases, one
must consider the processes in both the immune
response and the target organ. With regard to the
immune response, MS has long been considered to be
mediated by myelin protein-specific CD4+ T lympho-
cytes secreting T helper 1 (Th1) type cytokines such as
interferon gamma (IFNg) [8]. T lymphocytes and macro-
phages infiltrate the CNS and secrete pro-inflammatory
cytokines such as IFNg, interleukin-12 (IL-12), tumour
necrosis factor (TNFa) and IL-17 which then sets off a
cascade of events ultimately leading to demyelination of
axons. This acute demyelination leads to a conduction
block of neurons and clinical relapse results [9]. In con-
trast to the deleterious Th1 responses described above,
Th2 responses, which include the production of cyto-
k i n e ss u c ha sI L - 4 ,I L - 5a n dI L - 1 0 ,a r et h o u g h tt ob e
beneficial in MS. In murine systems, Th1 and Th2
immune responses are counter regulatory and, in states
of health, the two responses exist in a delicate balance
[10]. While there are clearly some differences in human
and murine systems, therapies for MS have nevertheless
aimed to either reduce Th1 or Th17 responses or to
increase Th2 responses. While the currently available
therapies with proven benefit in RR MS (interferon beta
1b, interferon beta 1a and copolymer-1) have numerous
possible mechanisms of action, several reports indicate
that they act, at least in part, through inducing favour-
able changes in the production of these cytokines
[11-14]. Other mediators of MS include chemokines and
adhesion molecules which play a role in the recruitment
of immune cells from the blood to the CNS lesion foci.
Tysabri, a drug which blocks adhesion molecules, was
shown to reduce relapses in MS [15]. Other immune
mechanisms in MS involve a variety of costimulatory
molecules. Trials to determine if blocking co-stimulatory
molecules may result in clinical benefit are ongoing.
Finally, as autoantigen presentation by macrophages and
dendritic cells in the peripheral immune system, as well
as by CNS resident microglia or astrocytes, may be
involved in ongoing inflammation, strategies to prevent
antigen presentation by these cells are also being pur-
sued as potential treatments.
As stated above, anti-inflammatory treatments have
been shown to reduce relapses in MS but have had only
a modest effect on halting the accumulation of perma-
nent disability. Particularly later in the disease, disability
accumulation has continued, despite robust and effective
immunosuppression with chemotherapeutic agents [16].
Thus, MS has both an inflammatory and a neurodegen-
erative component in its pathogenesis. Over the last
decade abundant neuroimaging and neuropathological
studies have described the significant neurodegenerative
process in MS. Neuroimaging has demonstrated atrophy
[17-22], particularly in grey matter [21,23,24]. This grey
matter atrophy has been shown to correlate better with
permanent disability than the white matter inflammatory
marker of gadolinium enhancing lesions [6,19,21]. Also,
abnormalities beyond classic white matter T2 hyperin-
tensities, within ‘normal appearing white matter’
(NAWM), have been seen using magnetization transfer,
spectroscopy and diffusion weighted imaging [25-31].
Furthermore, the degree of change in the NAWM may
be a predictor of future clinical progression [32]. Patho-
logical findings in MS have described cortical lesions
that were characterized by transected neurites (both
axons and dendrites) and apoptosis. There was very lit-
tle T and B cell infiltration. Activated microglia
ensheathed apical dendrites, neurites and neuronal peri-
karya [33,34]. Axonal transection has also been
described within white matter lesions raising the possi-
bility of Wallerian degeneration in white matter tracts.
In light of these clinical, neuroimaging and neuropatho-
logic observations there is now a consensus by MS
investigators that there is a need to discover a treatment
which is primarily designed as a neuroprotective agent
for MS. This neuroprotective agent should be taken in
combination with an anti-inflammatory treatment. The-
oretically, combination treatment with both an anti-
inflammatory agent and a neuroprotective agent would
have a greater impact upon the halting of permanent
disability accumulation in MS compared to treatment
with an anti-inflammatory agent alone.
Sex differences in MS
During reproductive ages (18-40), there is a distinct
female preponderance of autoimmune diseases including
MS [35]. Sex hormones and/or sex chromosomes may
be responsible for this enhanced susceptibility. In males,
the onset of MS tends to be relatively later in life
(30-40), coinciding with the beginning of the decline in
bioavailable testosterone (T) [36]. Thus, the female to
male ratio is greater in patients presenting with MS
before 20 years old (3.2:1) compared to the ratio in the
MS population as a whole (2:1) [37]. Interestingly, a
recent Canadian study found a disproportionate increase
in the incidence of MS in women [38]. This increase in
the sex ratio, approaching 4:1, was theorized to possibly
be of environmental origins. Alternatively, these data
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may merely be reflective of the propensity for neurolo-
gists to diagnose women with autoimmune disease. As
time passes, neurologists have more sensitive tools for
detecting early MS and with these come a growing
appreciation of the importance of early treatment in
slowing disability accumulation. Notably, the relatively
higher sex ratios in MS recently reported remain consis-
tent with the sex ratios that were previously known in
other autoimmune diseases such as rheumatoid arthritis
(RA) and systemic lupus erythematosus (SLE).
In general, it has been well documented that women
have more robust immune responses than men [39].
Females have a greater humoral response, as evidenced
by higher serum immunoglobulin concentrations than
males and a greater antibody response to various anti-
gens after immunization [40]. In addition, females reject
skin allografts faster and have a reduced incidence of
tumours, indicating that they also have a greater cellular
immune response [35]. Thisi sa l s ot r u ew h e nc o m p a r -
ing women and men with MS. Autoantigen (proteolipid
protein) specific immune responses from women were
characterized by higher levels of Th1 responses [41-43].
On the other hand, it is still a controversial whether the
disease course differs between the sexes remains contro-
versial. Despite the more robust immune responses in
women, some studies have suggested that men may
h a v eam o r ep r o g r e s s i v ec o u r s eo fd i s e a s e[ 3 6 , 4 4 , 4 5 ] .
Further, early neuroimaging studies suggested that
women have more inflammatory markers in the CNS,
while men have more neurodegenerative outcomes [46].
However, when both the clinical and neuroimaging data
were adjusted for age, these sex differences in progres-
sion and neurodegenerative outcomes became less
apparent. Together, these observations suggest that,
while susceptibility and immune responses are higher in
women than in men with MS, the rate of progression
and neurodegeneration may, surprisingly, be no differ-
ent. Thus, sex differences in the CNS should be consid-
ered independently of sex differences in the immune
system in MS, with the potential for opposing
influences.
The murine model of MS
While there is no perfect animal model of MS, experi-
mental autoimmune encephalomyelitis (EAE) is the
most widely used animal model for studying the patho-
genesis of MS. Decades of work have described the
immunology and the neuropathology of EAE. Immuno-
logic studies focused on myelin protein specific immune
responses including those directed against myelin basic
protein (MBP), proteolipid protein (PLP) and myelin oli-
godendrocyte protein (MOG). Much of what has been
theorized in MS with respect to immune responses was
based on the initial findings in EAE, including the role
for Th1 cytokines, IL17, chemokines, adhesion mole-
cules and co-stimulatory molecules. Regarding the neu-
ropathology of EAE, past studies focused on detailed
characterization of lesions with respect to the inflamma-
tory infiltrate composition, the level of demyelination,
the level of oligodendrocyte loss, microglial activation
and astrocytic scar formation [47-50]. Less attention has
focused on neurons, with only recent descriptions of a
relationship between axonal loss and disability [51]. Our
group and others have each described CNS pathology
‘beyond the lesion’ in normal appearing white matter
characterized by decreases in axon densities in white
matter tracts of the dorsal spinal cord [52-54]. Another
study described motor neuron dendritic abnormalites in
grey matter of spinal cords of mice with EAE [55] and
our group has published that neuronal staining in spinal
cord grey matter is abnormal even early during the
course of EAE [53]. Regarding neuroimaging ‘beyond
the lesion’ in EAE, diffusion tensor imaging (DTI)
changes have been described in dorsal cord and optic
nerve by others [52,56] and cerebellar grey matter atro-
phy has been described by our group [57]. Thus, while
EAE has been the prototypic Th1 mediated disease tool
used by immunologists for decades, more recently, EAE
has also been characterized with respect to its neurode-
generative component by neuroscientists.
Sex differences in the murine model of MS
EAE in the SJL strain of mice has been characterized to
have a sex bias that parallels that of multiple sclerosis,
with males being less susceptible to the disease than
females [58-62]. In part, this sex difference may result
from the protective effects of testosterone in male mice,
as suggested by studies demonstrating that the removal
of physiologic levels of testosterone from male mice via
castration increased disease susceptibility [63,64]. Also,
in animal models of other autoimmune diseases, where
a similar gender dimorphism exists [non-obese diabetic
(NOD) mice, thyroiditis and adjuvant arthritis), castra-
tion was shown to increase the disease prevalence and/
or the disease severity [65-68]. Further, testosterone
levels have been shown to be decreased in male mice
during EAE relapse [69]. Together, these data support
the hypotheses that endogenous androgens may be pro-
tective at physiologic levels.
Notably, however, while the SJL, the ASW and the
NZW strains of mice have an increased susceptibility to
EAE in females compared to males, the B10.PL and PL/J
have more susceptibility to disease in males compared
to females [70], while there is no sex bias in the C57BL/
6 strain [71,72]. Effects of removal of androgens in EAE
have previously been shown to be dependent upon
genetic background [72] and some autosomal gene
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one gender but not the other [73]. Thus, in the outbred
human population, the genetic background of some, but
not all, individuals may be permissive to sex effects.
Importantly, since overall there is a gender difference in
many autoimmune diseases in humans, we hypothesize
that the incidence of relatively permissive genetic back-
grounds are likely to be prevalent, not rare, occurrences.
Testicular hormones in the MS model
Sex differences in MS and the EAE model may be
related to sex hormones, sex chromosomes or both:
female sex hormones or male sex hormones may play a
role. This section will discuss a possible role for male
sex hormones.
To begin to test the role of endogenous androgens in
MS, the EAE model was used. Since EAE in the SJL
strain of mice had previously been characterized to have
ag e n d e rd i f f e r e n c et h a tp a r a l l e l e dt h a to fM S ,w i t h
males being less susceptible to disease than females
[61,62], the SJL strain was used. Protective effects of tes-
tosterone in male mice were shown by studies demon-
strating that the removal of physiologic levels of
testosterone from male mice via castration increased
disease susceptibility [63,72]. Finally, testosterone levels
were shown to be decreased in male mice during EAE
relapse [69]. Together, these data support the hypoth-
eses that endogenous androgens are protective at phy-
siologic levels in these autoimmune disease models.
As the MS population is genetically heterogenous, it
was then necessary to determine whether the protective
effect of endogenous androgens was a phenomenon that
was unique to the SJL strain. The C57BL/6 strain was
used since there was no sex bias in EAE in this strain
[70-72]. Disease severity did not differ between castrated
and sham C57BL/6 male mice, thereby indicating that
endogenous androgens are not protective in all genetic
backgrounds. A lack of a protective effect of endogenous
androgens in C57BL/6 mice was found to not be due to
lower endogenous levels of androgens in the C57BL/6
strain as compared to the SJL strain. Thus, equivalent
levels of endogenous androgens were shown to be pro-
tective in males of one genetic background but not
another [72]. This is consistent with findings that the
protection from disease observed in young male mice
was affected by the strain of origin of the Y chromo-
some [74]. Autosomal loci have been identified that
control susceptibility in several clinical subtypes of EAE
in both males and females [75]. A locus on chromosome
13 (eae 13) was linked to susceptibility of monophasic
remitting/non-relapsing EAE in males but not females.
It was hypothesized that a sex specific effect at eae 13
might be responsive to testosterone levels and, thereby,
give males a greater ability to control disease once it is
initiated. Interestingly, it has been shown that one gene
locus, rsl,i nt h er e g i o no feae 13, is capable of regulat-
ing sexually dimorphic traits [76]. Therefore it is possi-
b l et h a te n d o g e n o u sa n d r o g e n sm a yb ep r o t e c t i v ei na
g i v e ns t r a i nd e p e n d i n gu p o neae 13 allele inheritance.
Some genetic backgrounds may also carry other alleles
that are more sensitive to the effect of testosterone at a
given endogenous level.
Notably, a lack of protection by endogenous andro-
gens in a given genetic background did not preclude a
therapeutic effect of supplemental androgen treatment
in EAE. Thus, treatment was implemented using either
testosterone or 5a-dihydrotestosterone (DHT). DHT
w a su s e da si tc a n n o tb ec o n v e r t e dt oo e s t r o g e n s .
Indeed, not only were both androgen treatments shown
to be protective in gonadally intact males of a strain in
which endogenous androgens were protective (SJL) but
they were also protective in a strain in which endogen-
ous androgens were not protective (C57BL/6) [72].
These data indicated that, even in genetic backgrounds
that are not permissive to a protective effect of endo-
genous androgens, protection can still be provided by
supplemental exogenous androgen treatment. This sug-
gested that the mechanisms of disease protection may
differ between endogenous physiologic androgens and
supplemental supraphysiologic androgen treatment.
These preclinical data laid the groundwork for clinical
trials that aimed to treat males in the heterogeneous MS
population with testosterone.
Mechanisms underlying the protective effects of
androgens have been previously investigated, and a
number of studies have delineated immunological
changes in androgen treated mice [77-80]. The balance
between cytokines produced by Th1 and Th2 lympho-
cytes is considered central to the development of EAE
with Th1 cytokines (IFN-g and IL-12) being pro-inflam-
matory and Th2 cytokines (IL-10, IL-4 and IL-5) being
anti-inflammatory [35]. In vitro treatment of naïve T
cells from Vb8.2 TCR transgenic mice stimulated with
M B PA c1 - 1 1p e p t i d ei nt h ep r e s e n c eo ft e s t o s t e r o n e
resulted in increased production of IL-10 and IL-5 and
decreased production of IFN-g [79]. T cell lines from
PLP 139-151 immunized mice stimulated with PLP 139-
151 in the presence of DHT also resulted in increased
IL-10 and decreased IFN-g production [79]. In vivo,
androgen treatment has also been shown to effect cyto-
kine profiles. When splenocytes from mice with EAE
treated in vivo with DHT or placebo were stimulated
with MBP, those from DHT treated had increased IL-10
and decreased IFN-g [77]. Further, when splenoctyes
from healthy mice treated with DHT in vivo were
stimulated with anti-CD3 antibody, increased levels of
IL-10 and decreased levels IL-12 were observed [78].
Cytokine gene knockout mice were then used to show
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+ Tl y m -
phoctyes with a subsequent indirect decrease in IL-12
[78]. Together, these data indicated that one mechanism
through which exogenous androgen treatment is protec-
tive in EAE involves effects on cytokine production.
Testicular hormones in MS
Disease onset in females typically occurs soon after pub-
erty. In males, disease onset usually occurs later in life
(age 30-40), coinciding with the age at which serum tes-
tosterone levels begin to decline in normal healthy men
[81-85]. Interestingly, this phenomenon may also be
true of other autoimmune diseases. The onset of rheu-
matoid arthritis (RA) in men also takes place later in life
with a reported fourfold increase in incidence rates in
older men (ages 35-74) compared to younger men (ages
18-34). Further, the sex difference of RA in women ver-
sus men is 4:1 between ages 35-44, which decreases to
1.1:1, by age 75 [86]. Together, these observations sug-
gested that relatively high levels of testosterone in young
men after puberty may provide temporary protection
from autoimmune disease onset in those men who were
genetically predisposed to ultimately develop the disease.
Additionally, it has been reported that 24% of male
MS patients tested had significantly lower levels of tes-
tosterone compared to age-matched healthy men [87].
The reason for the decreased testosterone levels remains
unclear. It may be due to gonadal failure or to effects
on the hypothalamic-pituitary axis (HPA) such as stress
or hypothalamic lesions [69]. In men with MS and sex-
ual dysfunction, low testosterone levels have been pre-
viously shown to be associated with low luteinizing
hormone levels, thereby ruling out gonadal failure [69].
Interestingly, a decrease in free testosterone levels has
been reported in untreated men with new onset RA
[88], making the possibility of hypothalamic lesions in
the brain in MS less likely. An effect of the stress of
c h r o n i ci l l n e s so nt h eH P Am a yb et h em o s tl i k e l y
explanation for the relatively lower levels of testosterone
in men with chronic autoimmune diseases.
Data in EAE suggested that supplemental, exogenous
testosterone treatment may provide protection across
genetic backgrounds in men of the heterogeneous MS
population [72]. Thus, to investigate the possible effects
of testosterone treatment in MS, testosterone was admi-
nistered via transdermal application (AndroGel®) to men
with RR MS in a small pilot trial [89]. A crossover
design, using a within arm comparison of 6 months pre-
treatment to 12 months treatment, was employed to
reduce the effect of disease heterogeneity given the
small sample size, as previously described in MS [90].
Ten subjects with RR MS completed the study. At base-
line, all subjects had testosterone levels in the lower range
of normal. During daily treatment with testosterone,
serum testosterone levels rose 50% on average to the
higher range of normal. Scores from the Paced Auditory
Serial Addition Task (PASAT) component of the Multi-
ple Sclerosis Functional Composite (MSFC), a commonly
used cognitive test in MS, remained stable during the
first 6 months of treatment (months 3 and 6), trended
upward after 9 months and were significantly improved
by month 12 of treatment. There was also a trend for
improvement in spatial memory, consistent with previous
reports of testosterone mediated improvements in work-
ing and spatial memory in healthy non-hypogonadal
elderly men [91,92].
The 10 subjects had low levels of enhancing lesion
activity on brain MRI at baseline and this low level was
not significantly increased or decreased with treatment.
The most interesting finding of the study was the effect
on brain atrophy. There was a 67% reduction in the rate
of brain volume loss during treatment compared to that
seen at pre-treatment. Interestingly, the timing of the
cognitive improvements coincided with the slowing of
brain atrophy on MRI.
Finally, testosterone treatment was also shown to
favourably affect the immune system by inducing
decreasing CD4+ T cell percentage and increasing nat-
ural killer (NK) cells. In addition, peripheral blood lym-
phocytes (PBMC) production of IL-2 was significantly
decreased while transformin growth factor (TGF)b1 pro-
duction was increased. Furthermore, PBMCs obtained
during the treatment period produced significantly more
of neuroprotective factors brain-derived neurotrophic
factor (BDNF) and platelet-derived growth factor
(PDGF-BB) [93].
In summary, endogenous androgens are protective in
EAE in some strains but not others. However exogenous
supplemental treatment with androgens is protective
across the genetic backgrounds. In humans with MS, we
hypothesize that some, but not all, men may be of a
genetic background that provides the protective effect of
relatively high physiologic levels of testosterone that exist
in young men. This may mask the early presentation of
the relapsing remitting phase of the disease. As these
men age, testosterone levels gradually decline and clinical
MS onset is observed. Later, during the course of disease,
it is possible that the stress of chronic disease may affect
the hypothalamic pituitary axis which suppresses testos-
terone levels further, to within the low normal range.
Further clinical trials are warranted in order to determine
whether treatment with supplemental testosterone may
offer some protection in men with MS.
A second clinical observation
Ovarian hormones primarily include oestrogens and
progesterone. Sex differences in MS could be due, at
least in part, to sex differences in ovarian hormones.
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However, there is no evidence that ovariectomy precipi-
tates or aggravates MS. In contrast to the lack of evi-
dence that endogenous cycling levels of ovarian
hormones are major disease modifiers in MS, there is
abundant evidence that the state of being pregnant is
associated with disease protection. The effect of preg-
nancy appears to be due, in part, to a protective effect
of high levels of oestrogen during late pregnancy. Thus,
a second major clinical observation merges: pregnancy
is a major disease modifier in MS. The study of sex dif-
ferences in autoimmune disease includes: (1) research
addressing female:male differences in a given autoim-
mune disease; and (2) research focused on a major dis-
ease modifier which is inherent to being one sex. Thus,
in autoimmune disease, there are two major clinical
observations. First, females are more susceptible than
males. Second, pregnancy reduces relapses in females.
Both of these observations can be pursued with respect
to basic mechanism and translational potential.
With regard to this second clinical observation, it has
been appreciated for decades that symptoms of patients
with autoimmune diseases are affected by pregnancy
and the post partum period. The most well character-
ized observations include those seen in MS, RA and
psoriasis. These patients experience clinical improve-
ment during pregnancy with a temporary ‘rebound’
exacerbation post partum [35,94-100]. Interestingly,
women with SLE may experience an exacerbation of
symptoms with gestation [101]. This differential effect of
pregnancy on these diseases is thought to reflect the dif-
ference in immunopathogenesis of SLE as compared to
MS and RA.
What is the precise effect of pregnancy on MS? What
had been generally recognized for decades was that
there was a period of relative ‘safety’ with regard to
relapses during late pregnancy followed by a period of
increased relapses post partum. These clinical observa-
tions were supported by a small study of two patients
who underwent serial cerebral MRIs during pregnancy
and post partum. In both women there was a decrease
in MR disease activity (T2 lesion number) during the
second half of pregnancy and a return of MR disease
activity to pre-pregnancy levels in the first months post-
partum [102]. Other studies found that, in addition to
having a decrease in disease activity in patients with
established MS, the risk of developing the first episode
of MS was decreased during pregnancy compared to
non-pregnant states [100]. The most definitive study of
the effect of pregnancy on MS came in 1998 by the
Pregnancy in Multiple Sclerosis (PRIMS) Group [96].
Relapse rates were determined in 254 women with MS
during 269 pregnancies and for up to 1 year after deliv-
ery. Relapse rates were significantly reduced from 0.7
per woman year in the year before pregnancy to 0.2
during the third trimester. Rates then increased to 1.2
during the first 3 months post partum before returning
to pre-pregnancy rates. No significant changes were
observed between relapse rates in the first and second
trimester compared to the year prior to pregnancy.
Together, these data clearly demonstrated that the latter
part of pregnancy is associated with a significant reduc-
tion in relapses, while there is a rebound increase in
relapses post partum.
Since mechanisms of action of the approved therapies
for MS involve anti-inflammatory effects and, as these
treatments result primarily in a reduction in relapse
rates, it is logical to hypothesize that mechanisms
underlying the protective effect of pregnancy on MS
relapses involve anti-inflammatory effects. Pregnancy is
a challenge for the immune system. From the mother’s
standpoint, the fetus is an allograft as it harbours anti-
gens inherited from the father. It is evolutionarily advan-
tageous for the mother to transiently suppress cytotoxic,
cell mediated, Th1 type immune responses involved in
fetal rejection during pregnancy. However, not all
immune responses should be suppressed as humoral;
Th2 type immunity is needed for the passive transfer of
antibodies to the fetus. Thus, a shift in immune
responses with a downregulation of Th1 and an upregu-
lation of Th2 is thought to be necessary for fetal survival
[10,103-105]. Indeed, it has been shown that, in both
mice and humans, failure to shift immune responses in
this manner results in an increase in spontaneous abor-
tion [104,106,107]. This shift in immune responses from
Th1 to Th2 occurs both locally at the maternal fetal
interface [10,108,109] as well as systemically
[104,106,107,110-112]. The systemic shift away from
Th1 and toward Th2 was initially shown in murine sys-
tems by a decrease in mixed lymphocyte reactions of
splenocytes and an increase in antibody production dur-
ing pregnancy [112]. Antigen stimulated splenocytes
were then shown to produce less Th1 cytokines and
more Th2 cytokines when derived from pregnant mice
[106,110]. In humans, peripheral blood mononuclear
cells in women with successful pregnancies produced
IL10 but no IFNg, upon stimulation with trophoblast
antigens [104]. In another study, antigen- and mitogen-
stimulated PBMC derived from patients with normal
pregnancies demonstrated a decrease in the production
of IL2 and IFNg a n da ni n c r e a s ei np r o d u c t i o no fI L 4
and IL10, with the lowest quantities of IL-2 and IFNg
and the highest quantities of IL4 and IL10 present in
the third trimester of pregnancy [107]. During the third
trimester pregnancy, ex vivo monocytic IL12 production
was also found to be about threefold lower and TNFa
production was approximately 40% lower than postpar-
tum values [111]. Two recent studies have been
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ally for immune responses during pregnancy and post
partum. Gilmore et al. demonstrated that ex vivo stimu-
lated PBMCs had increased IFNg production post par-
t u ma sc o m p a r e dt ot h et h i r dt r i m e s t e ra n dm y e l i n
protein specific T cell lines derived from subjects in the
third trimester produced more IL10 [113], while
Al-Shammri et al.f o u n dt h a ts i xo ft h ee i g h tM S
patients’ ex vivo stimulated PBMCs showed a distinct
shift from a Th2 cytokine bias (IL4 and IL10) during
pregnancy, towards a Th1 cytokine bias (IFNg and
TNFa) after delivery [114]. In light of these data which
demonstrated a relative shift to Th2 systemically during
pregnancy, with a rebound back to Th1 post partum, it
becomes highly plausible that these alterations in the
immune response could underlie the improvement in
putative Th1 mediated autoimmune diseases during
pregnancy, as well as the exacerbation post partum.
Pregnancy is a complex event characterized by
changes in numerous factors which may impact the
CNS. These include increases in oestriol, oestradiol, pro-
gesterone and prolactin, to name a few [115]. Potential
neuroprotective effects of oestrogens and progesterone
will be discussed in depth below. Recently, it was shown
that pregnant mice have an enhanced ability to re-myeli-
nate white matter lesions and that prolactin regulates
oligodendrocyte precursor proliferation and mimics this
regenerative effect of pregnancy [116]. This finding may
be potentially exploited in pursuit of a therapeutic repair
strategy to increase remyelination. However, when con-
sidering the effect of prolactin treatment in neuroimmu-
nologic diseases such as MS, one must recall that
prolactin has pro-inflammatory properties which can
exacerbate disease, as has been shown in the MS model,
EAE [117]. Thus, when considering any pregnancy fac-
tor, its effects on both the CNS and the immune system
must be considered. Notably, the clinical observation
that breast feeding, which would be associated with a
prolonged state of increased levels of prolactin, had no
effect compared to no breast feeding with respect to the
post partum rate in MS [118]. A lack of a difference in
relapse rate may suggest that the pro-inflammatory
properties of increased prolactin during breast feeding
may not be clinically significant. On the other hand, the
relapse rate is a relatively insensitive, albeit important,
outcome measure. Future studies should compare
immune responses, enhancing lesions on MRI and pro-
lactin levels in MS women who are, or are not, breast
feeding post partum.
What is striking about pregnancy is that it represents
a state that is characterized by two important changes.
First, there is a downregulation of cellular immune
responses. This relative immunosuppression probably
occurs in order to prevent fetal rejection. Second,
pregnancy is characterized by the presence of potentially
neuroprotective hormones, such as oestrogens, proges-
terone and prolactin. It would seem evolutionarily
advantageous to have such neuroprotective factors pre-
sent as neuronal and oligodendrocyte lineage cells in the
f e t u sp r o g r e s st h r o u g hc r i t ical developmental windows
[119]. Together, the combined anti-inflammatory and
neuroprotective state of pregnancy, which is, perhaps,
aimed at protecting the fetus, is precisely what is needed
to protect the CNS during inflammatory attack in MS.
Treatment with ovarian hormones in EAE
It was shown over a decade ago that EAE in guinea
pigs, rats and rabbits improved during pregnancy [94].
Further, it was shown that relapsing-remitting EAE in
SJL mice improved during late pregnancy [120,121].
The EAE model was then used to determine if an
increase in levels of a certain hormone during preg-
nancy might be responsible for disease improvement.
Since oestrogens and progesterone increase progres-
sively during pregnancy to the highest levels in the
third trimester, these hormones were candidates for
possibly mediating a protective effect. Two oestrogens,
oestradiol and oestriol, increase progressively during
pregnancy. Oestradiol is otherwise present at much
lower fluctuating levels during the menstrual cycle in
non-pregnant women and female mice. Oestriol, in con-
trast, is made by the fetal placental unit and is not
otherwise present in non-pregnant states. Over the last
10 years it has been shown in numerous studies that
oestrogen treatment (both oestriol and oestradiol) can
ameliorate both active and adoptive EAE in several
strains of mice (SJL, C57BL/6, B10.PL, B10.RIII)
[122-130]. Oestriol treatment has also been shown to be
effective in reducing clinical signs in EAE when admi-
nistered after disease onset [129]. Finally, both oestra-
diol and oestriol have been shown to be efficacious in
both female and male mice with EAE [131].
Effects of oestrogen treatment in animal models of RA
are similar to those in EAE. Oestrogen treatment is
clearly protective in collagen induced arthritis (CIA) and
pharmacologic blocking of both nuclear ERa and ERb
receptors abolished this protection [132-135]. In con-
trast, oophorectomy ameliorates murine lupus, while
oestrogen treatment, even at physiologic doses, acceler-
ates disease [136-138]. The mechanism for the deleter-
ious effect of oestrogen on murine lupus appears to
involve, at least in part, an oestrogen induced effect on
genes involved in survival and apoptosis of B cells which
results in a skewing of naïve B cells towards autoimmu-
nity [139-142]. Opposite effects of oestrogen treatment
in EAE and CIA, as compared to oestrogen treatment in
lupus, are reminiscent of the opposite effects of preg-
nancy in the human autoimmune diseases they model.
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appears to be critical. A clinical amelioration of EAE
occurred when oestriol was used at doses to induce
serum levels which were physiologic with pregnancy. On
the other hand, oestradiol had to be used at doses sev-
eral fold higher than pregnancy levels in order to induce
the same degree of disease protection [128]. Thus, while
it is clear that high doses of oestradiol are protective in
EAE, it has not yet been clearly established whether low
doses of oestradiol are protective. Due to major differ-
ences in metabolic rates between humans and mice, it is
very difficult to determine what a low dose oestrogen in
an oral contraceptive pill in humans would equate to in
a mouse. Thus, one can only use available physiologic
benchmarks, such as the dose needed to induce a level
in blood equal to that in pregnant mice or the dose
needed to induce an oestrus level in an ovariectomized
mouse. Rigorous comparisons of blood levels in preg-
nant or oestrus mice, assessed in parallel with levels in
oestradiol treated mice are needed. Since ovariectomy
removes physiologic levels of oestradiol, as well as pro-
gesterone, data on the effect of ovariectomy on EAE is
somewhat informative in this regard. Some reports have
found that ovariectomy of female mice makes EAE
worse [125], while others have found that ovariectomy
does not have a significant effect on disease [121]. Thus,
it is controversial whether low levels of endogenous oes-
tradiol which fluctuate during the menstrual cycle have
a significant influence on EAE.
What is the effect of the other major ovarian hor-
mone, progesterone, in EAE? Theoretically progesterone
treatment could be beneficial as it had previously been
shown in other systems to aid in myelination by oligo-
dendrocytes [143,144]. However, while the severity of
EAE was significantly reduced in oestriol or oestradiol
treated mice as compared to placebo treated, treatment
with progesterone was indistinguishable from the pla-
cebo [129]. A variety of progesterone doses, ranging
from low (physiologic with menstrual cycle levels) to
moderate (physiologic with late pregnancy levels) to
very high (supraphysiologic), were used in combination
with oestrogen (either oestradiol or oestriol) in EAE and
n o n eo ft h ep r o g e s t e r o n ed o s e ssignificantly altered the
protective effect of oestrogen treatment on EAE disease
course [121]. The lack of an effect of progesterone treat-
ment on EAE was somewhat disappointing since proges-
terone had been shown to enhance remyelination in
vitro [144-146]. Interestingly, in the Lewis rat, progester-
one treatment alone was shown to deleterious, causing
increased motor deficits, increased inflammation and
increased neuronal apoptosis during acute EAE, while
oestrogen treatment in combination protected against
these deleterious effects of progesterone [147]. These
data in EAE are consistent with previous work by the
Holmdahl group in the mid 1990s which demonstrated
that treatment with oestrogens could ameliorate col-
lagen induced arthritis [128,132,135], while progesterone
treatment alone had no effect. Progesterone treatment
had only mild synergistic effects when used in combina-
tion with oestrogen treatment [148]. Together, these
data indicate that oestrogen, not progesterone, can med-
iate disease protection during EAE.
Protective mechanisms of oestrogen treatment (both
oestriol and oestradiol) in EAE clearly involve anti-
inflammatory processes, with oestrogen treated mice
having fewer inflammatory lesions in the CNS [129]. In
adoptive EAE in SJL mice, an increase in IL10, with no
change in IFNg, was observed in ex vivo stimulated
MBP specific responses, which was accompanied by an
increase in MBP specific antibody of the IgG1 isotype,
with no change in those of the IgG2a isotype [129]. In
active EAE in C57BL/6 mice, a decrease in TNFa, IFNg,
and IL6 has been observed, with an increase in IL5.
[122,123,130,131]. Oestrogen treatment has also been
shown to downregulate chemokines in the CNS of mice
with EAE and may affect expression of matrix matallo-
protease-9 (MMP-9), each leading to impaired recruit-
ment of cells to the CNS[125,127]. Oestradiol at
pregnancy levels, but not below, reduced IL17 and
increased PD-1 in T regulatory cells [149]. In addition
oestrogen treatment has been shown to impair the abil-
ity of dendritic cells to present antigen [124,150]. The
effect of oestrogen treatment on dendritic cell function
in EAE may involve upregulated expression of indolea-
mine 2,3-dioxygenase (IDO) [151]. IDO is an enzyme
involved in the catabolism of tryptophan which is
expressed in antigen-presenting cells of lymphoid organs
and in the placenta. It was shown that IDO prevents
rejection of the fetus during pregnancy, probably by
inhibiting alloreactive T cells [152] and it has been
shown that IDO expression in antigen-presenting cells
may also control autoreactive immune responses [153].
Finally, oestrogen treatment has recently been shown to
induce CD4+CD25+ regulatory T cells in EAE
[154,155]. Thus, oestrogen treatment has been shown to
be anti-inflammatory through a variety of mechanisms.
An anti-inflammatory effect of oestrogen treatment in
EAE does not preclude an additional more direct neuro-
protective effect. Oestrogens are lipophilic, readily tra-
versing the blood brain barrier, with the potential to be
directly neuroprotective [156-158]. Numerous reviews
have described oestrogen’s neuroprotective effects, both
in vitro and in vivo [157-159] in other model systems.
In vitro, oestrogens have been shown to protect neurons
in a variety of models of neurodegeneration, including
those induced by excitotoxicity and oxidative stress
[160-163]. Treatment with oestrogen decreased gluta-
mate-induced apoptosis and preserved electrophysiologic
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activation has also been demonstrated after oestrogen
treatment [166-168], along with modulation of the
astrocytic response to injury [169,170]. Oestrogen treat-
ment also protected oligodendrocytes from cytotoxicity
[171-173] as well as accelerated oligodendrocyte process
formation [174]. In vivo studies have shown that oestro-
gen treatment can be neuroprotective in animal models
of Parkinson’s disease, cerebellar ataxia, late onset leuko-
dystrophy, stroke and spinal cord injury, often by redu-
cing apoptosis via upregulation of the anti-apototic
genes bcl-2 and bcl-x [158,159,175-181]. Oestrogens
have also been shown in vitro and in vivo to increase
dendritic spine formation and synapses on CA1 pyrami-
dal cells of the hippocampus in healthy rats, resulting in
improved working spatial memory [182-186].
Given the neuroprotective effect of oestrogen treat-
ment in other disease models, it was then addressed
whether oestrogen treatment might be neuroprotective
in EAE, the MS model. Oestradiol treatment not only
reduced clinical disease severity and was anti-inflam-
matory with respect to cytokine production in periph-
eral immune cells, it also decreased CNS white matter
inflammation and demyelination. In addition,
decreased neuronal staining (NeuN+/b3-tubulin
+/Nissl), accompanied by increased immunolabelling of
microglial/monocyte (Mac 3+) cells surrounding these
abnormal neurons, was observed in grey matter of
spinal cords of placebo treated EAE mice at the ear-
liest stage of clinical disease, and treatment with oes-
tradiol significantly reduced this grey matter pathology.
Thus, oestradiol treatment was not only anti-inflam-
matory but also neuroprotective in the prevention of
both white and grey matter pathology in spinal cords
of mice with EAE [53].
Determining which oestrogen receptor mediates the
protective effect of an oestrogen treatment in disease is
of central importance for future development of selec-
tive oestrogen receptor modifiers which aim to maxi-
mize efficacy and minimize toxicity. The actions of
oestrogen are mediated prima r i l yb yn u c l e a ro e s t r o g e n
receptors, ERa and ERb, although non-genomic mem-
brane effects have also been described [187]. Originally
it was thought that ERa and ERb would each have dis-
tinct tissue distributions, thereby providing a means
through which use of selective oestrogen receptor modi-
fiers (SERMs) could improve tissue selectivity. However,
the relationship between ERa and ERb became complex,
with most tissues expressing detectable level of each of
these receptors [188]. The two receptors at times did,
and at other times did not, co-localize to the same cells
within a given tissue [189,190]. Further, in some tissues
the two receptors were shown to act synergistically,
while in other tissues they acted antagonistically. Tissue
specific differences in biologic outcomes are thought to
be due, in part, to tissue specific differences in transcrip-
tion factors which become activated upon binding of
each oestrogen receptor (ER) by ligand [191-193].
Despite the fact that both ERa and ERb are expressed
in both the immune system and the CNS
[188,189,194,195], oestrogen receptor knock out mice
have been used to show that the protective effect of oes-
trogen treatment (oestradiol and oestriol) in EAE was
dependent upon the presence of ERa,n o tE R b
[126,130]. However, whether targeted stimulation of
ERa in developmentally normal mice was both neces-
sary and sufficient for the oestrogen mediated protection
in EAE remained unknown. A highly selective ERa
ligand, propyl pyrazole triol (PPT) [196], was then used
to determine whether stimulation of ERa in develop-
mentally normal mice would be sufficient for the oestro-
gen mediated protection in EAE. Our group [53], and
another [197], have each found that treatment with this
ERa selective ligand was indeed sufficient for protection
in EAE and was capable of inducing favourable changes
in autoantigen specific cytokine production in the per-
ipheral immune system (decreased TNFa, IFNg and IL6,
with increased IL5), as well as decreasing pathology in
the CNS.
Subsequently, bone marrow chimeras were used by
Garidou et al. to show that the disease ameliorating
effects of oestradiol treatment in EAE were not depen-
dent upon ERa signalling in blood derived inflammatory
cells [198]. This suggested that the functionally signifi-
cant target for oestrogen’s actions in vivo during EAE is
cells within the CNS. Given that treatment with either
oestradiol or the ERa ligand was both anti-inflamma-
tory and neuroprotective, the central question then
became whether the neuroprotective properties of
oestrogen treatment in EAE were or were not depen-
dent upon the anti-inflammatory properties. Notably, a
study had suggested that an anti-inflammatory effect
was necessary to observe oestrogen mediated neuropro-
tection in stroke [199].
Since treatment with an ERa ligand is so anti-inflam-
matory in the peripheral immune system of EAE mice,
there is a dramatic reduction in immune cells going into
the CNS. While myelin and axons are preserved in the
CNS, it cannot be discerned whether the effect of ERa
ligand treatment is solely anti-inflammatory (and only
indirectly neuroprotective) versus whether it is both
anti-inflammatory and directly neuroprotective. In this
context, direct neuroprotection refers to protection of
CNS cells which is not merely due to reducing the
immune attack. It is very difficult to treat only the CNS
with an ERa ligand and block all effects in the periph-
ery. However, differential neuroprotective and anti-
inflammatory effects of ERa and ERb ligand treatment
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might be directly neuroprotective in EAE [54]. Clinically,
ERa ligand treatment abrogated disease at the onset and
throughout the disease course. In contrast, ERb ligand
treatment had no effect at disease onset, but promoted
recovery during the chronic phase of the disease. ERa
ligand treatment was anti-inflammatory in the systemic
immune system, while ERb ligand treatment was not.
However, treatment with either the ERa or the ERb
ligand was neuroprotective as evidenced by reduced
demyelination and preservation of axon numbers in
white matter [200,201]. Thus, by using the ERb selective
ligand, the anti-inflammatory effect from the neuropro-
tective effect of oestrogen treatment were dissociated
and it was shown that neuroprotective effects of oestro-
gen treatment were not necessarily dependent upon
anti-inflammatory properties.
Currently, it is unknown whether the neuroprotective
effects of oestrogen treatments in EAE are directly
mediated by binding oestrogen receptors on neurons or
are indirectly mediated by binding oestrogen receptors
on non-neuronal CNS cells. While neurons express oes-
trogen receptors and could be a target for oestrogen’s
actions, glial cells (oligodendrocytes, astrocytes and
microglia) also express oestrogen receptors [202]. Mye-
lin/axonal interactions, as well as astrocytic support for
neurons, each make it possible that oligodendrocytes or
astrocytes, respectively, may be the targets for oestro-
gen’s protective effect on neurons and axons in vivo.
Further, the neuroprotective effect of estrogens in vivo
during EAE could also be mediated by reducing micro-
glia activation since microglial activation can be deleter-
ious for neurons.
Treatment with ovarian hormones in MS
Levels of oestrogens that are lower than those which
occur during pregnancy, such as levels induced by doses
in oral contraceptives or hormone replacement therapy,
may or may not be high enough to be protective in MS.
While some studies have attempted to simulate a situa-
tion of treatment with oral contraceptives in EAE mice
and have shown an effect on disease [122,127], doses
used in mice are not readily translatable to humans. In
fact, the data in humans thus far has suggested that
treatment with oral contraceptives is not likely to sup-
press MS. The incidence rate of MS onset in both for-
mer and current oral contraceptive users was not
different from that in never-users [203]. It is not sur-
prising that former use of oral contraceptives in healthy
women would have no effect on subsequent risk to
develop MS, since one would not anticipate that the
effect of treatment on the immune system would be
permanent. However, the fact that incidence rates for
MS in current oral contraceptive pill users were not
decreased, compared to never-users, suggests that the
oestrogens in oral contraceptives are not of sufficient
type or dose to ameliorate the immunopathogenesis of
MS, even temporarily, during current use. This remains
an unresolved issue as controversial results emerge with
respect to the use of oral contraceptives and MS risk
during current use [204,205]. Studies of hormone repla-
cement therapy and effects on disease activity in rheu-
matoid arthritis can provide further clues with respect
to which doses of oestrogens could potentially be pro-
tective in MS [206]. In a randomized placebo controlled
trial of transdermal oestradiol in 200 postmenopausal
RA patients, who continued other anti-rheumatic medi-
cations, it was found that those who achieved a serum
oestradiol level > 100 pmol/L had significant improve-
ments in articular index, pain scores, morning stiffness
and sedimentation rates, while those with lower oestra-
diol levels did not demonstrate improvement [207].
There has been no consistent correlation between dis-
ease markers in MS or RA and hormone levels during
the menstrual cycle in females. Together, these reports
suggest that it is probable that a sustained level of a suf-
ficient dose of an oestrogen will be necessary to amelio-
rate disease activity in MS and RA.
Since oestriol is the major oestrogen of pregnancy and
since an oestriol dose which yielded a pregnancy level in
mice was protective in disease [129], oestriol was admi-
nistered in a prospective pilot clinical trial to women
with MS, in an attempt to recapitulate the protective
effect of pregnancy on disease [208]. A crossover study
was used whereby patients were followed for 6 months
pre-treatment to establish baseline disease activity which
included cerebral MRI every month and neurologic
exam every 3 months. The patients were then treated
with oral oestriol (8 mg/day) for 6 months and then
observed for 6months or more months in the post treat-
ment period. There were six RR patients and four SP
patients who finished the 18 month study period. The
RR MS subjects were then retreated with oral oestriol
and progesterone in a four month extension phase. Oes-
triol treatment resulted in serum oestriol levels which
approximated levels observed in untreated healthy con-
trol women who were 6 months pregnant. Interestingly,
a significant decrease in a prototypic in vivo Th1
response, the delayed type hypersensitivity response to
the recall antigen tetanus, was observed at the end of
the 6 month treatment period as compared to the
pre-treatment period. When PBMCs were stimulated
ex vivo, a favourable shift in cytokine profile (decreased
TNFa, increased IL10 and IL5) was observed during
treatment as compared to baseline [209]. On serial
MRIs, the RR patients demonstrated an 80% reduction
in gadolinium enhancing lesions within 3 months of
treatment, compared to pre-treatment [208] and this
Voskuhl Biology of Sex Differences 2011, 2:1
http://www.bsd-journal.com/content/2/1/1
Page 11 of 21improvement in enhancing lesions correlated with the
favourable shift in cytokine profiles [209]. Importantly,
gadolinium enhancing disease activity gradually returned
to baseline in the post treatment period and the favour-
able cytokine shift also returned to baseline. Further, in
the 4 month extension phase of the study, both the
decrease in brain enhancing lesions and the favourable
immune shift, returned upon retreatment with oestriol
in combination with progesterone in the RR MS group.
These latter data have important translational implica-
tions since progesterone treatment is needed in combi-
nation with oestrogen treatment to prevent uterine
endometrial hyperplasia when oestrogens are adminis-
tered for a year or more in duration. These results indi-
cate that treatment with progesterone in combination
with oestriol did not neutralize the beneficial effect of
oestriol treatment on these biomarkers of disease. A
multi-centre, double-blind, placebo-controlled trial of
oestriol treatment in RR MS is now ongoing in the USA.
Now we will review, and attempt to reconcile, findings
of oestrogen treatment in basic science with oestrogen
treatment in clinical trials in other diseases, mostly neu-
rodegenerative diseases. Despite very promising results
in various in vitro and in vivo animal systems describing
neuroprotective effects of oestrogen treatment (reviewed
above), a large study of oestrogen replacement therapy
in mild to moderate Alzheimer’s disease, with subjects
an average age of 75 years, yielded disappointing results
with no significant effects on clinical outcomes [210]. It
has been hypothesized that either the age of the subject
population, or the stage of disease, may be critical in
whether a neuroprotective effect of oestrogen treatment
can be appreciated [211]. Adequate levels of oestrogen
receptors, or associated intracellular cofactors, may no
longer be optimally expressed in either hormonally
senescent, or significantly diseased, brains. Indeed the
effect of oestrogen treatment on the blood brain barrier
has been shown to be quite different when comparing
senescent versus younger rats [212]. Clinical reports also
indicate differential effects of oestrogen treatment
depending on age and disease status. Oestrogen replace-
ment had no effect on cognition in elderly menopausal
women [213], while it preserved cognition in younger
women undergoing surgical hysterectomy [214,215]. In a
large trial assessing the effects of oestrogen treatment in
stroke, treatment had no effect on cognition in women
with stroke who had cognitive impairment at baseline
but treatment reduced the risk for cognitive decline in
those with normal cognition at baseline [216]. Finally,
an improvement in cognitive function was observed
with oestriol treatment in early RRMS, but not in late
SPMS [208]. A ‘healthy cell bias of oestrogen action’ has
been hypothesized to explain the disparity between pro-
mising results of oestrogen treatment in animal models
of neurodegenerative diseases versus disappointing
results in oestrogen treatment in some neurodegenera-
tive disease trials [217]. Efficacy of oestrogen treatment
appears to depend critically upon its administration
early, as a preventative therapy, before neurodegenera-
tion has occurred [210]. Also, results may be more
promising if there is not a prolonged period of
hypoestrogenicity before treatment with oestrogens
[199]. Plaques in coronary arteries, a biomarker for
cardiovascular risk, were reduced when conjugated
equine oestrogens were administered relatively early to
women 50-59 who had undergone hysterectomy [218].
The question is then prompted regarding whether oes-
trogen treatment might also need be to instituted rela-
tively early in autoimmune or neurodegenerative
diseases. Together, these data warrant further study of
treatments with oestrogens, in MS and other diseases,
which consider the age and disease duration of the
subjects.
In summary, there has been shown that there is a
protective effect of relatively high doses of oestrogens
(oestradiol and oestriol) within the late pregnancy
range in the MS model, while a role for lower endo-
genous fluctuating levels of estrogens during the men-
strual cycle are controversial. In addition, there is no
evidence that progesterone treatment is protective in
the MS model. Mechanisms underlying the protective
effects of high dose oestrogens include both anti-
inflammatory and neuroprotective properties. Whether
treatment with supplemental oestrogens may be pro-
tective in women with MS is currently being investi-
gated through clinical trials.
Sex chromosome effects in autoimmune disease
A non-mutually exclusive alternative to sex hormone-
induced differences in autoimmune disease is a direct
genetic effect on the immune system. That is, specific
gene products, which are not induced by gonadal hor-
mones but are expressed in a sexually dimorphic man-
ner in the immune system, could induce sex-specific
patterns of immune system development or function.
In male mammals, the Y-linked gene Sry is expressed
in cells of the undifferentiated gonadal ridges to cause
them to differentiate into Sertoli cells, which begins the
differentiation of the testes [219]. Once the testes have
formed, they secrete hormones distinct from those of
the ovary and these hormonal differences generate sex
differences in many non-gonadal tissues such as the
external genitalia, immune system and central nervous
system. Indeed, the effects of these hormones account
for the majority of sex differences in non-gonadal tissues
identified to date. However, there are other genetic dif-
ferences between males and females arising from the
difference in sex chromosome complement that could
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[220,221]. There are other Y genes whose role in non-
gonadal tissues has been little studied and there are also
differences in X gene expression arising from the differ-
ence in X chromosome complement. As it has been
much easier to study the effects of gonadal hormones
than these possible direct effects of X and Y genes, the
sexually differentiating effects of hormones are much
better understood. The focuso ft h i ss e c t i o nw i l lb eo n
whether direct actions of X or Y genes on tissues may
also be important in autoimmunity.
As gonadectomy gives only limited information about
putative effects of genes on sex chromosomes, we turned
to a mouse strain that had been used by investigators
studying sexually dimorphic development [221-226]. In
these mice, the testis-determining gene Sry is ‘moved’
from the Y chromosome to an autosome by successive
deletion from the Y chromosome and introduction of an
Sry transgene onto an autosome. Thus, the inheritance of
genes causing testicular differentiation is separated from
the Y chromosome, and the Y chromosome can be pre-
sent or absent in phenotypic male (testis-bearing) mice
and it can be present or absent in phenotypic female
(ovary-bearing) mice. The Y chromosome deficient in the
Sry gene is denoted Y
- and XY
-Sry male mice carry the
Sry transgene. When this mouse is mated with an XX
f e m a l e ,f o u rp r o g e n yr e s u l t :X Xf e m a l e s ,X Y
- females,
XXSry males and XY
-Sry males.
In order to determine the role of genes on sex chro-
mosomes on autoantigen specific immune responses, we
backcrossed the outbred MF1Y
-Sry mice onto the SJL
strain. We chose the SJL strain because a sex bias had
been clearly shown in the SJL, with female SJL mice
more susceptible than males to EAE [60-62,77,227].
Further, autoantigen specific immune responses had
been shown to differ between females and males
immunized with either MBP or PLP, with greater levels
of Th1 cytokines produced in draining lymph node
cells (LNCs) of females as compared to males
[61,79,80,227,228]. In order to address direct effects of
sex chromosomes on immune responses, the immune
responses would be examined in SJL mice which differed
in the complement of sex chromosomes, while having
the same gonadal type. Gonadal females (XX and XY
-)
were ovariectomized prior to immunization to remove an
effect of adult circulating female hormones on immune
responses. Immune responses were significantly higher in
ovariectomized XY
- mice compared to ovariectomized
XX mice. These included increased levels of IFNg,T N F a
and IL-10 in supernatants of autoantigen stimulated
immune cells. Further, when gonadal male mice were
castrated prior to immunization, immune responses were
significantly higher in castrated XY
-Sry mice as compared
to castrated XXSry mice. While these data are consistent
with an immunostimulatory role for a gene on the X
chromosome [39], these findings cannot distinguish from
an immunosuppressive effect of a gene on the Y chromo-
some [229].
The finding that the XY
- sex chromosome comple-
ment, compared to the XX, was relatively more stimula-
tory with respect to cytokine responses (IFNg,T N F a,
IL10) during autoantigen specific stimulation supported
the concept of direct effects of sex chromosomes on
autoimmunity, but the precise role in autoimmune dis-
ease remained unknown. IFNg and TNFa may have
either disease promoting or disease protective effects
depending on the dose and timing of their production,
while IL10 is generally considered to be protective in
EAE. In addition, there are numerous other cytokines,
chemokines, adhesion molecules and co-stimulatory fac-
tors that play a role in EAE pathogenesis and they, too,
could theoretically be affected by sex chromosome com-
plement. Thus, to directly assess the role of sex chromo-
some complement in disease, EAE was induced in mice
with the informative sex chromosome complements.
Specifically, both females and males were gonadecto-
mized to remove any intercurrent effects of sex hor-
mones which might mask effects of sex chromosomes
[230]. SJL castrated male mice that were either XXSry
or XY
-Sry, had active EAE induced with proteolipid
protein peptide (PLP) 139-151 peptide. Clinical disease
course was significantly more severe in XXSry mice, as
compared to XY
-Sry mice. This significant difference
in disease severity also occurred when comparing ovar-
iectomized female XX versus XY
- mice. Further, in
adoptive EAE, CNS pathology revealed higher levels of
inflammation in mice that had received autoantigen
specific cells derived from XX mice compared to those
from XY
- mice. Together, these data showed that the
XX sex chromosome complement, as compared to the
XY
-, was associated with a greater ability to induce
EAE [231].
As it had been previously shown that no sex bias
existed in EAE in the C57BL/6 strain of mice [70-72], it
was then ascertained whether an effect of sex chromo-
somes could be found in this strain. Thus, the Sry defi-
cient Y chromosome from the original outbred MF1
mice [232] was backcrossed onto the C57BL/6 strain.
Both females and males were gonadectomized in order
to remove any effects of sex hormones which might
mask the effects of sex chromosomes. C57BL/6
castrated male mice that were either XXSry or XY
-Sry
had active EAE induced with (MOG) 35-55 peptide. In
contrast to results in the SJL, clinical disease courses
were no different when comparing XXSry mice with
XY
-Sry mice [231]. There was also no difference in dis-
ease when comparing ovariectomized female XX versus
XY
- mice. Together, these data indicated that, when a
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male difference in EAE (the SJL), a sex chromosome
effect was present. In contrast, when a strain was used
that is not characterized by a female to male difference
in EAE (the C57BL/6), a sex chromosome effect was not
present. The presence of a sex chromosome effect in
one strain, but not another, revealed an interaction
between sex chromosome complement and genetic
background. Notably, effects of sex hormones in EAE
have also previously been shown to be dependent on
genetic background [72] and some autosomal gene lin-
kages to susceptibility to MS have been identified in one
gender but not the other [73]. Thus, in the outbred
human population, the genetic background of some, but
not all, individuals may be permissive to sex chromo-
some or sex hormone effects. Notably, as overall there is
a sex difference in many autoimmune diseases in
humans, we hypothesize that relatively permissive
genetic backgrounds are likely to be prevalent, not rare,
in occurrence.
In light of the fact that lupus in humans is character-
i z e db ya9 : 1f e m a l ep r e p o n d e r a n c ea n ds i n c ei th a d
previously shown that pristane induced lupus in SJL
mice was characterized by greater susceptibility in
females as compared to males [233], it was then deter-
mined whether the effect of sex chromosome comple-
ment observed in SJL mice with EAE was unique to
this disease or was more pervasive across autoimmune
diseases. Thus, the role of sex chromosome comple-
ment in pristane induced lupus was investigated. Ovar-
iectomized female XX and XY
- SJL mice and castrated
male XXSry and XY
-Sry mice were injected with pris-
tane and monitored daily for signs of disease. By 26
weeks only 30.8% of XX mice had survived, 68.4% of
XY
- mice had survived. This significantly greater dis-
ease severity in XX mice also occurred when compar-
ing castrated male XXSry mice with XY
-Sry.K i d n e y
pathology and levels of anti-dsDNA antibodies also
revealed more severe disease in XX as compared to
XY
- mice [231].
Together, data using the informative Sry transgenic
mice indicated that the XX sex chromosome comple-
ment was disease promoting as compared to the XY
-
complement. It remains to be determined whether this
effect is due to: (1) gene(s) unique to the Y chromo-
some; (2) a higher dose of X genes which escape X-inac-
tivation in XX mice; or (3) paternal imprinting of X
genes which are present in XX, but not XY
-, mice [221].
Consistent with a potential X dosage effect in our lupus
model, XXY men and XX women both have a similar
high risk of developing lupus, while the incidence of
lupus in XO females is very low [234,235]. Since these
sex chromosome differences in humans are confounded
by differences in sex hormones during both
development and adulthood, it is difficult to distinguish
between a sex chromosome effect versus a sex hormone
effect in humans.
Conclusions
The study of sex differences in autoimmune disease
includes: (1) research addressing female versus male dif-
ferences in a given autoimmune disease; and (2)
research focused on a major disease modifier which is
inherent to being one sex. In autoimmune diseases,
there are two major clinical observations related to sex:
first, females are more susceptible than males; and, sec-
ond, pregnancy reduces relapses in females. Both of
these observations can be pursued with respect to basic
mechanism and translational potential.
With regard to the clinical observation that females
are more susceptible than males, the state of being
female indeed confers more susceptibility risk to develop
autoimmune disease than any gene or environmental
factor identified to date. Basic research indicates a pro-
tective role for high levels of androgens in young males,
with little role for fluctuating levels of ovarian hormones
in females. Thus clinical trials of treatment with andro-
gens in autoimmune disease are warranted. Further, a
role for sex hormones is not mutually exclusive of a role
for sex chromosomes. Indeed, the XX sex chromosome
complement has been shown to be disease promoting as
compared to XY
-. This sex chromosome effect is true in
autoimmune disease models that are distinct in immu-
nopathogenesis, including both cell mediated and anti-
body mediated diseases. The precise gene on X or Y
remains to be determined.
With regard to the clinical observation that late preg-
nancy in females with MS is associated with an 80%
reduction in relapses, this reduction is more dramatic
than any of the first line drugs currently available to
treat MS which reduce relapses by 30%-50%. A protec-
tive role for high levels of estrogens during late preg-
nancy has been shown in animal models. This is true
for cell mediated, but not antibody mediated, diseases.
Thus, clinical trials of treatment with pregnancy level
oestrogens in cell mediated autoimmune disease are
warranted.
Thus, the study of clinically relevant sex differences, if
understood at the basic science level, can lead to new
treatments for a variety of autoimmune diseases.
Glossary
25’ timed walk = a measure of gait speed used as part of
the MS Functional Composite Measure. The 25 foot
timed walk is a mobility and leg function performance
test in which MS patients are timed to walk 25 ft.
Those patients unable to complete the 25 ft walk, need
assistance or use a wheel chair, are noted as such.
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with an emulsion of adjuvant and stimulatory protein
(autoantigen). This approach enables the study of dis-
ease inductor and effector phases of experimental
demyelinating disease.
Adoptive EAE = CD4 T lymphocytes specific for the
autoantigen are transferred from an immunized donor
mouse to a naive recipient mouse, with disease then
occurring in the recipient mouse. This method of EAE
allows for the separation of the induction and effector
phases of the disease.
Allograft = a transplant of tissue, cells, or organs from
a genetically non-identical source of the same species.
Aromatase = an enzyme of the cytochrome P450
superfamily, which functions to aromatize androgens to
produce oestrogens.
Diffusion-weighted imaging = a type of MRI in which
in vivo images of biological tissue are weighted with the
microstructural characteristics of water diffusion within
the tissue.
Gadolinium enhancing lesions = a delineated area of
increased MR signal intensity on T1-weighted spin-echo
images, compared to normal-appearing surrounding
brain tissue following intravenous injection of a gadoli-
nium chelate.
Expanded Disability Status Scale (EDSS) = a method
for quantifying disability in MS patients, in which neu-
rologists assess eight functional systems: pyramidal, cer-
ebellar, brainstem, sensory, bowel and bladder, visual,
cerebral and other.
Hashimoto’s thyroiditis = a type of autoimmune thyr-
oid disease in which the immune system attacks and
destroys the thyroid gland, causing a dysfunctional pro-
duction of thyroid hormones.
Lymph node cells (LNCs) = cells cultured from the
lymph nodes, organs belonging to the lymphatic system
and found throughout the body. The lymph nodes
house several immune cell types including B cells, T
cells, plasma cells, macrophages, reticular cells and
white blood cells.
Nine-hole peg task = the nine-hole peg task is used to
measure fine manual dexterity of the right and left
hands in MS patients.
Non-obese diabetic (NOD) mice = a mouse strain sus-
ceptible to spontaneous development of autoimmune
insulin dependent diabetes mellitus.
Normal appearing white matter (NAWM) = myeli-
nated area of the CNS that appears intact and healthy
via MRI but that may contain abnormalities and lesions.
Oophorectomy = another term for ovariectomy, the
surgical removal of the female reproductive organs,
ovaries.
Paced Auditory Serial Addition Task (PASAT) = a
cognitive task given to MS patients to measure auditory
information processing speed and flexibility, as well as
calculation ability.
Primary biliary cirrhosis = an autoimmune disease of
the liver, in which the small bile ducts are slowly and
progressively destroyed. This causes bile accumulation,
which damages surrounding tissue and can lead to scar-
ring, fibrosis, cirrhosis and eventual liver failure.
Pristane = a natural saturated alkaline found primarily
in shark liver oil. Pristane is used as an immunologic
adjuvant to induce systemic lupus erythematosus (SLE).
PD-1 = programmed death marker 1.
Sedimentation rate = also referred to as erythrocyte
sedimentation rate (ESR), the speed at which red blood
cells (erythrocytes) fall to the bottom of a fine glass tube
filled with a RA patient’s blood. A faster ESR indicates a
higher level of inflammation, and aids in determining
the severity of the condition.
Sertoli cells = a type of supporting cell found in the
seminiferous tubules within the testes, important for
maturation of spermatocytes.
Sjogren’s syndrome = a chronic autoimmune disease
in which white blood cells attack systemic moisture pro-
ducing glands, such as the tear duct and salivation
glands.
T2 lesion = a hyperintense region in an MRI scan,
where normal appearing white matter would be dark.
T2-weighted imaging = a type of MRI contrast, in
which water concentration affects image intensity. As an
example, oedema would appear as a hyperintense spot
on the MRI scan and white matter would appear dark
in this contrast type.
Uterine endometrial hyperplasia = a condition in
which the endometrium lining of the uterus excessively
proliferates.
Wallerian degeneration = a process that results from
t h ec u t t i n go rc r u s h i n go fan e r v ef i b r ei nw h i c ht h e
axon degenerates after it is detached from its neuronal
cell body.
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